Paper3908116
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
Bonneterre J and 9 others. Eur J Cancer Clin Oncol, 1985. Cited by 44 papers, by iCite.
Cite this record
ConductScience Library. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Papers, record 3908116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3908116
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminoglutethimide | Major topic |
| Breast Neoplasms | Major topic |
| Aged | |
| Clinical Trials as Topic | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Random Allocation | |
| Time Factors |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8354015 | Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. | Clin Pharmacokinet | 1993 | https://conductscience.org/library/papers/8354015 | PubMed |
| 7949205 | First generation aromatase inhibitors--aminoglutethimide and testololactone. | Breast Cancer Res Treat | 1994 | https://conductscience.org/library/papers/7949205 | PubMed |
| 3690808 | Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3690808 | PubMed |
| 3427227 | Variations in lipoproteins during aminoglutethimide therapy. | Breast Cancer Res Treat | 1987 | https://conductscience.org/library/papers/3427227 | PubMed |
| 3048976 | Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. | Drugs | 1988 | https://conductscience.org/library/papers/3048976 | PubMed |
| 2679845 | Treatment of breast cancer with aromatase inhibitors--current status and future prospects. | Br J Cancer | 1989 | https://conductscience.org/library/papers/2679845 | PubMed |
| 2013115 | Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. | Cancer Chemother Pharmacol | 1991 | https://conductscience.org/library/papers/2013115 | PubMed |
| 1493356 | Aromatase inhibitors in malignant diseases of aging. | Drugs Aging | 1992 | https://conductscience.org/library/papers/1493356 | PubMed |
| 1283847 | Systemic therapy of advanced breast cancer. | Drugs | 1992 | https://conductscience.org/library/papers/1283847 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3908116
GET https://conductscience.org/api/papers/v1/3908116/authors